These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27580623)

  • 1. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care.
    Allan V; Banerjee A; Shah AD; Patel R; Denaxas S; Casas JP; Hemingway H
    Heart; 2017 Feb; 103(3):210-218. PubMed ID: 27580623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation based on a CHA
    Methavigul K; Chichareon P; Yindeengam A; Krittayaphong R
    BMC Cardiovasc Disord; 2023 Dec; 23(1):623. PubMed ID: 38114960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
    Lip GY; Skjøth F; Nielsen PB; Larsen TB
    Thromb Haemost; 2015 Oct; 114(4):826-34. PubMed ID: 26223245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores.
    Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Marín F; Lip GYH
    Thromb Haemost; 2021 Aug; 121(8):1107-1114. PubMed ID: 33296920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischemic stroke risk estimation in patients without oral anticoagulation: an observational cohort study based on secondary data from Germany.
    Wicke FS; Schaller MA; Karymova K; Beyer M; Müller BS
    BMC Cardiovasc Disord; 2019 Apr; 19(1):94. PubMed ID: 31014253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
    Blann AD; Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Int J Cardiol; 2015 Dec; 201():693-8. PubMed ID: 26379097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation.
    Shah SJ; Singer DE; Fang MC; Reynolds K; Go AS; Eckman MH
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006212. PubMed ID: 31707823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation.
    Yao X; Abraham NS; Alexander GC; Crown W; Montori VM; Sangaralingham LR; Gersh BJ; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Cirrhosis in Patients With Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for Stroke Prevention?
    Kuo L; Chao TF; Liu CJ; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Lip GYH; Chen SA
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28645935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study.
    Anjum M; Ariansen I; Hjellvik V; Selmer R; Kjerpeseth LJ; Skovlund E; Myrstad M; Ellekjær H; Christophersen IE; Tveit A; Berge T
    Eur Heart J; 2024 Jan; 45(1):57-66. PubMed ID: 37995254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
    Am Heart J; 2018 Mar; 197():27-34. PubMed ID: 29447781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHA2DS2-VASc and SAMe-TT2R2 scores as predictors of recurrence for nonvalvular atrial fibrillation patients on vitamin K antagonists after radiofrequency catheter ablation.
    Zhao J; Zhou D; Chen M; Zhuo C; Lin Z; Zheng L; Wang Q
    J Cardiovasc Med (Hagerstown); 2020 Mar; 21(3):200-208. PubMed ID: 31977539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Net Clinical Benefit of Dabigatran Over Warfarin in Patients With Atrial Fibrillation Stratified by CHA
    Chan PH; Huang D; Lau CP; Chan EW; Wong IC; Lip GY; Tse HF; Siu CW
    Can J Cardiol; 2016 Oct; 32(10):1247.e15-1247.e21. PubMed ID: 27118057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28729407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
    Milentijevic D; Lin JH; Connolly N; Chen YW; Kogan E; Shrivastava S; Sjoeland E; Alberts MJ
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105715. PubMed ID: 33743312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Lane DA; Buller H; Lip GY
    Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR
    Thompson LE; Maddox TM; Lei L; Grunwald GK; Bradley SM; Peterson PN; Masoudi FA; Turchin A; Song Y; Doros G; Davis MB; Daugherty SL
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.